|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REPORT
1Department of Physiology, New York Medical College, Valhalla, New York; 2Scuola Superiore Sant'Anna, Settore di Medicina, Pisa, Italy; and 3Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio
Submitted 14 July 2005 ; accepted in final form 10 November 2005
Acute inhibition of nitric oxide (NO) synthase causes a reversible alteration in myocardial substrate metabolism. We tested the hypothesis that prolonged NO synthase inhibition alters cardiac metabolic phenotype. Seven chronically instrumented dogs were treated with N
-nitro-L-arginine methyl ester (L-NAME, 35 mg·kg1·day1 po) for 10 days to inhibit NO synthesis, and seven were used as controls. Cardiac free fatty acid, glucose, and lactate oxidation were measured by infusion of [3H]oleate, [14C]glucose, and [13C]lactate, respectively. After 10 days of L-NAME administration, despite no differences in left ventricular afterload, cardiac O2 consumption was significantly increased by 30%, consistent with a marked enhancement in baseline oxidation of glucose (6.9 ± 2.0 vs. 1.7 ± 0.5 µmol·min1·100 g1, P < 0.05 vs. control) and lactate (21.6 ± 5.6 vs. 11.8 ± 2.6 µmol·min1·100 g1, P < 0.05 vs. control). When left ventricular afterload was increased by ANG II infusion to stimulate myocardial metabolism, glucose oxidation was augmented further in the L-NAME than in the control group, whereas free fatty acid oxidation decreased. Exogenous NO (diethylamine nonoate, 0.01 µmol·kg1·min1 iv) could not reverse this metabolic alteration. Consistent with the accelerated rate of carbohydrate oxidation, total myocardial pyruvate dehydrogenase activity and protein expression were higher (38 and 34%, respectively) in the L-NAME than in the control group. Also, protein expression of the constitutively active glucose transporter GLUT-1 was significantly elevated (46%) vs. control. We conclude that prolonged NO deficiency causes a profound alteration in cardiac metabolic phenotype, characterized by selective potentiation of carbohydrate oxidation, that cannot be reversed by a short-term infusion of exogenous NO. This phenomenon may constitute an adaptive mechanism to counterbalance cardiac mechanical inefficiency.
heart; metabolism; nitric oxide
This article has been cited by other articles:
![]() |
P. F. Soto, P. Herrero, K. B. Schechtman, A. D. Waggoner, J. M. Baumstark, A. A. Ehsani, and R. J. Gropler Exercise training impacts the myocardial metabolism of older individuals in a gender-specific manner Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H842 - H850. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Williams, C. Ojaimi, K. Qanud, S. Zhang, X. Xu, F. A. Recchia, and T. H. Hintze Coronary nitric oxide production controls cardiac substrate metabolism during pregnancy in the dog Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2516 - H2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Cuong, M. Warda, N. Kim, W. S. Park, J. H. Ko, E. Kim, and J. Han Dynamic changes in nitric oxide and mitochondrial oxidative stress with site-dependent differential tissue response during anoxic preconditioning in rat heart Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1457 - H1465. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |